<DOC>
	<DOCNO>NCT00542789</DOCNO>
	<brief_summary>The purpose study assess efficacy esomeprazole ( D961H ) 20 mg versus placebo daily 24 week treatment involve patient history gastric and/or duodenal ulcer receive daily nonsteroidal anti-inflammatory drug ( NSAID ) therapy evaluate presence absence gastric and/or duodenal ulcer throughout treatment period ( 24 week ) term efficacy prevention gastric and/or duodenal ulcer</brief_summary>
	<brief_title>Comparative Efficacy &amp; Safety Study Esomeprazole Versus Placebo Prevention Gastric Duodenal Ulcers With NSAID</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Medical history gastric and/or duodenal ulcer A diagnosis chronic condition ( rheumatoid arthritis , osteoarthritis , lumbago , etc ) require daily NSAID use , least 20 year age Having gastric duodenal ulcer active healing stage accord Sakita/Miwa classification History esophageal , gastric duodenal surgery Having severe liver disease chronic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>gastrointestinal</keyword>
	<keyword>GI</keyword>
	<keyword>NSAID</keyword>
	<keyword>Japan</keyword>
	<keyword>Japanese</keyword>
	<keyword>Gastric ulcer</keyword>
	<keyword>duodenal ulcer</keyword>
</DOC>